Table 6.
No. of studies | % | |
---|---|---|
Confirmation (where applicable) of the CB1/CB2 target | 207 | 69 |
Effects on motor activity | 124 | 33 |
Investigate pharmacokinetics | 26 | 7 |
Tissue concentrations | 25 | 7 |
Electrophysiology | 20 | 5 |
Potential toxic effects | 19 | 5 |
Measure markers of neuronal activity | 19 | 5 |
Effect on anxiety/depression | 11 | 3 |
Effects on dependency | 10 | 3 |
CB2, cannabinoid type 2.